-
In recent years there has been considerable interest in the utilization of biomarkers to assist in the prediction of risk for cardiovascular events, including mortality.
-
The cardiotoxicity of anthracyclines and other agents may negatively affect clinical outcomes in cancer survivors. Data in other clinical situations and animal data on anthracycline-induced cardiomyopathy suggests that angiotensin-converting enzyme inhibitors (ACEI) may ameliorate this cardiotoxicity.
-
Sacher and colleagues collected data on all patients diagnosed with Brugada syndrome who received an implantable cardioverter defibrillator (ICD) in 14 centers between 1993 and 2005.
-
After 8-10 years, atherosclerosis of saphenous vein grafts and symptoms of ischemia are common. Since repeat bypass surgery is associated with a higher mortality than first surgeries, percutaneous interventions (PCI) are preferred for vein graft disease.
-
In this paper Pappone and his colleagues report a randomized study comparing circumferential pulmonary vein ablation (CPVA) to antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation who had previously failed at least one trial with antiarrhythmic drugs.
-
Several important papers have been published in the last 2 months, none more important than the realization that breast cancer rates have dropped precipitously since the publication of the Women's Health Initiative (WHI) in 2002.
-
-
For defibrillation success there is no significant difference between monophasic and biphasic shocks.
-
Significant reductions in door-to-balloon time for acute STEMI are accomplished by reducing the time required to activate the cardiac catherization lab.
-
Patients with coronary artery disease who have received intra-coronary, drug-eluding stents (DES) may benefit from longer courses of clopidogrel than is currently standard.
